CST, 35364SF, RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying RHAMM/CD168/HMMR. Validated for WB,IHC,IHC,IF,F. Highly specific and rigorously validated in-house, RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #35364) is ready to ship. Product Usage Information This product is the carrier free version of product #87129. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 87129 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total RHAMM/CD168 protein. Non-specific staining was observed in kidney proximal tubules. Species Reactivity: Human, Mouse, Rat, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RHAMM/CD168 protein. The antigenic peptide spans a region that is 100% conserved among the four isoforms of RHAMM/CD168 reported in Uniprot. Background Receptor for Hyaluronic acid-Mediated Motility (RHAMM, known also as CD168 or HMMR) was first identified as a putative receptor for hyaluronic acid (HA) that modulated HA-mediated cell motility (1). RHAMM/CD168 is functionally similar to the HA receptor CD44; however in contrast to CD44, RHAMM/CD168 does not contain a transmembrane domain or a signal peptide leader sequence, and so is not targeted exclusively to the cell membrane (1). RHAMM/CD168 has multiple isoforms; some are reportedly exported to the cell membrane in response to signaling by growth factors and cytokines (e.g., TGF-β) (2, 3), whereas others have been implicated in intracellular functions including mitotic spindle regulation (4). Cell surface RHAMM/CD168 is localized to membrane ruffles, consistent with proteins that regulate cell motility (1). Numerous research studies have reported that the expression of RHAMM/CD168 is positively associated with cancer cell growth, motility and/or metastasis (5-7), in addition to HA-mediated inflammation (8), suggesting the potential for therapeutic approaches that target HA-receptor mediated signaling (9,10). Alternate Names CD168; HMMR; Hyaluronan mediated motility receptor; hyaluronan-mediated motility receptor (RHAMM); IHABP; intracellular hyaluronic acid binding protein; Intracellular hyaluronic acid-binding protein; MGC119494; MGC119495; Receptor for hyaluronan-mediated motility; RHAMM Specification REACTIVITY: H M R Mk SENSITIVITY: Endogenous MW (kDa): 85 Source/Isotype: Rabbit IgG